Lifestance Health Group (LFST) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual Meeting scheduled for June 2, 2026, will be held virtually to maximize shareholder participation and accessibility.
Shareholders will vote on director elections, auditor ratification, executive compensation, and other business.
Proxy materials and annual report are available online, with multiple voting methods provided.
Voting matters and shareholder proposals
Shareholders will elect two directors to serve until 2029.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is on the agenda.
Advisory vote on executive compensation for named executive officers.
Shareholders may submit proposals for future meetings, subject to deadlines and requirements.
Board of directors and corporate governance
Board is divided into three classes with staggered terms to ensure continuity and stability.
Board size will be reduced to eight members after the meeting.
Majority of directors are independent under Nasdaq rules.
Board committees include audit, compensation, nominating/governance, and quality/compliance, each with defined responsibilities.
Annual board and committee performance reviews are conducted.
Sponsor Investors (TPG and Summit) retain nomination rights for board seats based on ownership levels.
Latest events from Lifestance Health Group
- Q2 2026 revenue up 26% to $435.4M, net income $23.6M, guidance and share buybacks increased.LFST
Q2 2026 - National mental health leader posts strong growth, raises 2026 outlook, and expands margins.LFST
Investor presentation - Hybrid care, rapid growth, and focus on quality outcomes drive industry leadership.LFST
46th Annual William Blair Growth Stock Conference - Hybrid mental health provider targets mid-teens EBITDA margins by 2028 amid strong industry growth.LFST
Bank of America Global Healthcare Conference 2026 - Revenue up 21% to $403.5M, net income $14.2M, and 2026 guidance raised on strong growth.LFST
Q1 2026 - Director elections, auditor ratification, and say-on-pay top the agenda for the virtual annual meeting.LFST
Proxy filing - Record revenue and earnings growth, margin expansion, and $100M share repurchase announced.LFST
Q4 2025 - Q2 revenue up 20%, Adjusted EBITDA doubled, and guidance raised for 2024.LFST
Q2 2024 - Margin expansion and strategic M&A set to drive growth beyond 2025, despite near-term payer headwinds.LFST
Goldman Sachs 45th Annual Global Healthcare Conference